A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years With Newly-diagnosed Philadelphia-negative ALL.

Principal Investigator

Justin Watts

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20220275

Clinical Trial Summary

A Multi-center, Open-label, Single-arm Phase 2/3 Trial
Evaluating the Safety and Pharmacokinetics of
Calaspargase Pegol for Treatment of Adults Aged 22 To
>65 Years* with Newly-diagnosed Philadelphia-negative
ALL

Phase

Phase II/III

Funding Agency/Sponsor

Industrial

Disease

Leukemia

Contact Information

Phone Number +1 (305) 2434624